Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathwaysYozo Mitsui(San Francisco VA Medical Center), Hiroaki Shiina(Shimane University)OncotargetMarch 7, 201510.18632/oncotarget.3445Cited by 26SaveCiteExport RISWatch citationsRelated PapersCYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma|BMC Cancer|2015|55